Bryostatin 1
Alzheimer's Disease
Neurotrope Bioscience, Inc.Small moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 73/ 100
Competitive context
317 Active assets in the Alzheimer's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Akiva Mintz | Phase 4 | BBB |
Cipralex NYU Langone Health | Phase 4 | BBB |
Namenda Carnot Laboratories | Phase 4 | BBB |
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) Anhui Provincial Hospital | Phase 4 | BBB |
PROPOFOL Nyree Penn | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Bryostatin 1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →